Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis

Hepatology. 2000 Jan;31(1):49-53. doi: 10.1002/hep.510310110.

Abstract

Genetic susceptibility to type 1 autoimmune hepatitis is indicated by a preponderance of female subjects and strong associations with human leukocyte antigens (HLA) DRB1*0301 and DRB1*0401. The gene encoding cytotoxic T-lymphocyte antigen-4 (CTLA-4) on chromosome 2q33 may also influence autoimmunity. To determine the frequency and significance of the exon 1 adenine (A)-guanine (G) base-exchange polymorphism for CTLA-4 in patients with type 1 autoimmune hepatitis, 155 northern European Caucasoid patients and 102 ethnically-matched control subjects were tested by polymerase chain reaction. The genotype distribution was significantly different in patients compared to controls (AA = 50/155 patients vs. 51/102 controls; AG = 84/155 patients vs. 38/102 controls; GG = 21/155 patients vs. 13/102 controls, chi(2) = 8.94, P =.011). This difference was caused by a significant over-representation of the G allele in patients compared to controls (105/155 patients vs. 51/102 controls, chi(2) = 8.34, P =.004, odds ratio = 2.12). The GG genotype was associated with a significantly higher mean serum aspartate transaminase level (P =. 03), greater frequency of antibodies to thyroid microsomal antigens (P =.004) and was found more commonly in patients with HLA DRB1*0301 (P =.02). Treatment outcomes, however, were not affected by the genotype. The CTLA-4 G allele is more common in patients with type 1 autoimmune hepatitis and may represent a second susceptibility allele. Furthermore, there may be synergy between the HLA-DRB1*0301 and the GG genotype in terms of disease risk.

MeSH terms

  • Abatacept
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents / therapeutic use
  • Antigens, CD
  • Antigens, Differentiation / genetics*
  • Azathioprine / therapeutic use
  • CTLA-4 Antigen
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease*
  • Genotype
  • HLA-DR Antigens / genetics
  • HLA-DRB1 Chains
  • Hepatitis, Autoimmune / drug therapy
  • Hepatitis, Autoimmune / genetics*
  • Humans
  • Immunoconjugates*
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • Prednisone / therapeutic use
  • T-Lymphocytes, Cytotoxic / immunology*
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • HLA-DR Antigens
  • HLA-DRB1 Chains
  • HLA-DRB1*03:01 antigen
  • HLA-DRB1*04:01 antigen
  • Immunoconjugates
  • Immunosuppressive Agents
  • Abatacept
  • Azathioprine
  • Prednisone